Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1404-1412

  Park, Jinah ^a   Park, Eunju ^a   Han, Sae Won ^a,b   Im, Seock Ah ^a,b   Kim, Tae You ^a,b   Kim, Woo Ho ^a   Oh, Do Youn ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Gastric cancer; P cadherin; PF 03732010

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; GENOMIC DNA; MESSENGER RNA; P CADHERIN; PF 03732010; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TREATMENT DURATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; RECEPTOR PROTEIN-TYROSINE KINASES; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866729869     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9710-9     Document Type: Article

References (25)

1. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ. (2008) Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 9(3):279-287. doi:10.1016/S1470-2045(08)70072-X
2. Park J, Song SH, Kim TY, Choi MC, Jong HS, Lee JW, Kim NK, Kim WH, Bang YJ. (2004) Aberrant methylation of integrin alpha4 gene in human gastric cancer cells. Oncogene 23. (19):3474-3480. doi:10.1038/sj.onc.1207470
3. Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK, Bang YJ. (2001) Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells. Cancer Res 61(11):4628-4635
4. Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, LeszczynieckaM, Sellers WR, Lengauer C. (2006) Validating cancer drug targets. Nature 441(7092):451-456. doi:10.1038/nature04873
5. Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y. (2008) Identification of a novel tumorassociated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 14(20):6487-6495
6. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC. (2007) P-cadherin expression in breast cancer: a review. Breast Cancer Res 9(5):214
7. Kim MA, Jung EJ, Lee HS, Lee HE, Yang HK, Oh DY, Bang YJ, Kim WH. (2010) P-cadherin expression in gastric carcinoma: its regulation mechanism and prognostic significance. Hum Pathol 41. (6):877-885. doi:10.1016/j.humpath.2009. 04.031
8. Milicic A, Harrison LA, Goodlad RA, Hardy RG, Nicholson AM, Presz M, Sieber O, Santander S, Pringle JH, Mandir N, East P, Obszynska J, Sanders S, Piazuelo E, Shaw J, Harrison R, Tomlinson IP, McDonald SA, Wright NA, Jankowski JA. (2008) Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res 68(19):7760-7768. doi:10.1158/0008-5472.CAN-08-0020
9. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC. (2005) P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11. (16):5869-5877. doi:10.1158/1078-0432.CCR-05-0059
10. Hibi K, Kitamura YH, Mizukami H, Goto T, Sakuraba K, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y. (2009) Frequent CDH3 demethylation in advanced gastric carcinoma. Anticancer Res 29(10):3945-3947
11. Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y. (2005) Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rhofamily GTPases. Cancer Res 65(8):3092-3099. doi:10.1158/0008.5472. CAN-04-3646
12. Van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, Vander Haeghen Y, Bracke M. (2005) P-cadherin promotes cell-cell adhesion and counteracts invasion in human melanoma. Cancer Res 65(19):8774-8783. doi:10.1158/0008-5472.CAN-04-4414
13. Ronaghi M, Uhlen M, Nyren P. (1998) A sequencing method based on real-time pyrophosphate. Science 281(5375):363-365
14. Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynow E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender SL, Anderes K, Christensen JG, Vanarsdale T. (2010) PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res. doi:10.1158/1078- 0432.CCR-10-1343
15. Tennant DA, Duran RV, Gottlieb E. (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10(4):267-277. doi:10.1038/nrc2817
16. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer. (ToGA)': a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X
17. Kim TY, Bang YJ, Robertson KD. (2006) Histone deacetylase inhibitors for cancer therapy. Epigenetics 1(1):14-23
18. Pulukuri SM, Estes N, Patel J, Rao JS. (2007) Demethylationlinked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res 67(3):930-939. doi:10.1158/0008-5472.CAN-06-2892
19. Kwon O, Jeong SJ, Kim SO, He L, Lee HG, Jang KL, Osada H, Jung M, Kim BY, Ahn JS. (2010) Modulation of E-cadherin expression by K-Ras; involvement of DNA methyltransferase-3b. Carcinogenesis 31(7):1194-1201. doi:10.1093/carcin/bgq071
20. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J. (2009) A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15(6):489-500. doi:10.1016/j. ccr.2009.03.022
21. Patel IS, Madan P, Getsios S, Bertrand MA, Maccalman CD. (2003) Cadherin switching in ovarian cancer progression. Int J Cancer 106(2):172-177. doi:10.1002/ijc.11086
22. Huang H, Bhat A, Woodnutt G, Lappe R. (2010) Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10(8):575-585. doi:10.1038/nrc2894
23. Martin V, Liu D, Fueyo J, Gomez-Manzano C. (2008) Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol 23(6):773-780
24. Nakayama T, Yoshizaki A, Kawahara N, Ohtsuru A, Wen CY, Fukuda E, Nakashima M, Sekine I. (2004) Expression of Tie-1 and 2 receptors, and angiopoietin-1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors. Histopathology 44(3):232-239
25. Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-Manzano C. (2009) Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene 28. (24):2358-2363. doi:10.1038/onc.2009.103